Your browser doesn't support javascript.
loading
Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.
Planas, Delphine; Staropoli, Isabelle; Michel, Vincent; Lemoine, Frederic; Donati, Flora; Prot, Matthieu; Porrot, Francoise; Guivel-Benhassine, Florence; Jeyarajah, Banujaa; Brisebarre, Angela; Dehan, Océane; Avon, Léa; Bolland, William Henry; Hubert, Mathieu; Buchrieser, Julian; Vanhoucke, Thibault; Rosenbaum, Pierre; Veyer, David; Péré, Hélène; Lina, Bruno; Trouillet-Assant, Sophie; Hocqueloux, Laurent; Prazuck, Thierry; Simon-Loriere, Etienne; Schwartz, Olivier.
Afiliação
  • Planas D; Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France. delphine.planas@pasteur.fr.
  • Staropoli I; Vaccine Research Institute, Créteil, France. delphine.planas@pasteur.fr.
  • Michel V; Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France.
  • Lemoine F; Pathogenesis of Vascular Infections Unit, Institut Pasteur, INSERM, Paris, France.
  • Donati F; G5 Evolutionary Genomics of RNA Viruses, Institut Pasteur, Université Paris Cité, Paris, France.
  • Prot M; Bioinformatics and Biostatistics Hub, Paris, France.
  • Porrot F; G5 Evolutionary Genomics of RNA Viruses, Institut Pasteur, Université Paris Cité, Paris, France.
  • Guivel-Benhassine F; National Reference Center for Respiratory Viruses, Institut Pasteur, Paris, France.
  • Jeyarajah B; G5 Evolutionary Genomics of RNA Viruses, Institut Pasteur, Université Paris Cité, Paris, France.
  • Brisebarre A; Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France.
  • Dehan O; Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France.
  • Avon L; National Reference Center for Respiratory Viruses, Institut Pasteur, Paris, France.
  • Bolland WH; National Reference Center for Respiratory Viruses, Institut Pasteur, Paris, France.
  • Hubert M; National Reference Center for Respiratory Viruses, Institut Pasteur, Paris, France.
  • Buchrieser J; National Reference Center for Respiratory Viruses, Institut Pasteur, Paris, France.
  • Vanhoucke T; Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France.
  • Rosenbaum P; Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France.
  • Veyer D; Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France.
  • Péré H; Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France.
  • Lina B; Humoral Immunology Laboratory, Institut Pasteur, Université Paris Cité, INSERM U1222, Paris, France.
  • Trouillet-Assant S; Laboratoire de Virologie, Service de Microbiologie, Hôpital Européen Georges Pompidou, Paris, France.
  • Hocqueloux L; Functional Genomics of Solid Tumors (FunGeST), Centre de Recherche des Cordeliers, INSERM, Université de Paris, Sorbonne Université, Paris, France.
  • Prazuck T; Laboratoire de Virologie, Service de Microbiologie, Hôpital Européen Georges Pompidou, Paris, France.
  • Simon-Loriere E; Functional Genomics of Solid Tumors (FunGeST), Centre de Recherche des Cordeliers, INSERM, Université de Paris, Sorbonne Université, Paris, France.
  • Schwartz O; Laboratoire de Virologie, Institut des Agents Infectieux, Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon, France.
Nat Commun ; 15(1): 2254, 2024 Mar 13.
Article em En | MEDLINE | ID: mdl-38480689
ABSTRACT
The unceasing circulation of SARS-CoV-2 leads to the continuous emergence of novel viral sublineages. Here, we isolate and characterize XBB.1, XBB.1.5, XBB.1.9.1, XBB.1.16.1, EG.5.1.1, EG.5.1.3, XBF, BA.2.86.1 and JN.1 variants, representing >80% of circulating variants in January 2024. The XBB subvariants carry few but recurrent mutations in the spike, whereas BA.2.86.1 and JN.1 harbor >30 additional changes. These variants replicate in IGROV-1 but no longer in Vero E6 and are not markedly fusogenic. They potently infect nasal epithelial cells, with EG.5.1.3 exhibiting the highest fitness. Antivirals remain active. Neutralizing antibody (NAb) responses from vaccinees and BA.1/BA.2-infected individuals are markedly lower compared to BA.1, without major differences between variants. An XBB breakthrough infection enhances NAb responses against both XBB and BA.2.86 variants. JN.1 displays lower affinity to ACE2 and higher immune evasion properties compared to BA.2.86.1. Thus, while distinct, the evolutionary trajectory of these variants combines increased fitness and antibody evasion.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Limite: Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: França País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Limite: Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: França País de publicação: Reino Unido